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Introduction
Positron emission tomography (PET) with amyloid ligands 
has revolutionized neuroimaging of aging and dementia 
in the past decade by enabling the detection and quanti-
fi cation of amyloid plaques, a core pathologic feature of 
Alzheimer’s disease (AD) [1]. Th e fi rst specifi c tracer for 
amyloid-beta (Aβ) applied in human studies was 
carbon-11 (11C)-labeled Pittsburgh Compound B (PIB). 
PIB is an analogue of thiofl avin-T that, at PET tracer 
concentrations, binds to fi brillar Aβ deposits with high 
sensitivity and specifi city [2,3]. PIB binds to both extra-
cellular amyloid plaques (composed primarily of the 
Aβ 1–42 peptide (Aβ1–42)) and vascular amyloid deposits 
(consisting mainly of Aβ  1–40 peptides) [4]. At PET 
tracer concentrations, PIB does not bind to non-Aβ 
inclusions such as neurofi brillary tangles or Lewy bodies 
[5,6] or to brain homogenates from patients with non-Aβ 
dementia [7].
PIB-PET has rapidly become an integral part of research 
studies on cognitive aging and the evolution of AD. Th e 
20-minute half-life of 11C, however, limits its use to 
research centers equipped with a cyclotron, and precludes 
widespread clinical application. More recently, a second 
generation of amyloid tracers labeled with fl uorine-18 
(18F, 110-minute half-life) has been developed, making it 
feasible to produce and distribute amyloid tracers for 
clinical use [8]. Th ree 18F amyloid imaging agents are in 
advanced stages of development: fl utemetamol, a 
3’-fl uoro analog of PIB; fl orbetapir, a styrylpyridine 
derivative; and fl orbetaben, a derivative of stilbene. Th ese 
tracers have performed comparably with PIB in clinical 
populations, although nonspecifi c white matter binding 
appears to be higher [9-11]. PIB, fl orbetapir and fl ute-
metamol have been validated prospectively compared 
with the autopsy diagnosis of AD, and in vivo tracer 
binding of all three shows high correlation with post-
mortem measures of fi brillar Aβ [3,9,12].
In addition to research applications, amyloid imaging 
has great potential as a diagnostic tool because it directly 
detects a core feature of the molecular pathology of AD. 
Th is stands in contrast to currently available diagnostic 
imaging techniques in dementia, which detect the down-
stream eff ects of pathology on the brain, such as synaptic 
dysfunction (fl uorodeoxyglucose (FDG)-PET) and neuronal 
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loss (magnetic resonance imaging (MRI)/computed 
tomography) – events that are thought to occur late in 
the disease cascade [13]. Indeed, the clinical utility of 
amyloid tracers is currently being debated by regulatory 
agencies [14].
In the present review, we focus on potential clinical 
applications of amyloid imaging. We summarize the litera-
ture on amyloid imaging in a range of neurodegenerative 
conditions, most of which consists of PIB studies. Data 
from 18F tracer studies are presented when available. We 
restrict our review to tracers that specifi cally bind to Aβ, 
and therefore do not discuss fl uoro-dicyano-dimethyl-
amino-naphthalenyl propene, a tracer that binds to a 
number of pathologic inclusions that have an amyloid 
conformation [15]. We comment on the potential clinical 
utility of amyloid PET in a variety of clinical scenarios, 
and provide examples from patients enrolled in a study of 
amyloid imaging at our institution. Finally, we summarize 
our recommendations for clinical use of amyloid imaging, 
and discuss limitations and unresolved questions related 
to this exciting new technique.
Amyloid PET in various clinical populations
Cognitively normal elderly
Most cognitively healthy normal controls (NC) do not 
show appreciable amyloid tracer binding (Figure 1). 
Elevated PIB binding is found in 10 to 30% of NC [16,17], 
however, and this is similar to observed rates of amyloid 
pathology in autopsy studies of normal aging [18]. In 
some cases, the extent and distribution of amyloid 
pathology in NC is indistin guishable from that found in 
AD [19]. Increasing age and the presence of the apo-
lipoprotein E ε4 allele (ApoE ε4) are the major predictors 
of PIB-positivity in NC [17,20]. Indeed, PIB binding is 
found in 18% or less of subjects below the age of 70, in 
26% of individuals aged 70 to 79  years, and in 30% of 
those aged 80 to 89 years. ApoE ε4 increases the overall 
prevalence of positive scans from 21% in noncarriers to 
49% in carriers, and shows dose and age eff ects. PIB-
positivity in NC has also been asso ciated with a family 
history of AD, and with subjective cognitive impairment 
[21,22]. 18F fi ndings in NC have largely been in agreement 
with PIB fi ndings showing similar prevalence, and 
relationships with age and ApoE [9-11,23].
Th e signifi cance of a positive amyloid scan in a cogni-
tively normal individual is uncertain. Some studies have 
found negative correlations between PIB and episodic 
memory in this population [16,24], while other studies 
found no diff erences across cognitive measures between 
PIB-positive and PIB-negative controls [25]. More consis-
tently, cross-sectional studies have found AD-like struc-
tural and functional brain changes in PIB-positive NC, 
such as hippocampal and temporo-parietal atrophy 
[24,26] and decreased resting-state connectivity in the 
default mode network [27,28]. Two retrospective studies 
reported an association between PIB-positivity and 
declining cognition [29,30]. In the largest prospective 
cohort, PIB-positivity was associated with declining 
memory and visuospatial performance [31], and was the 
strongest predictor of functional decline (conversion 
from clinical dementia rating of 0 to 0.5 or 1) [32]. Th ese 
cross-sectional and early longitudinal data have strength-
ened the notion that many (although probably not all) 
PIB-positive NC are in a preclinical phase of AD [33], but 
this hypothesis requires further longitudinal investigation.
From a diagnostic perspective, the signifi cant baseline 
rate of amyloid-positive NC emphasizes that amyloid-
positivity is not synonymous with AD, and that amyloid 
scans cannot be interpreted in lieu of a detailed clinical 
evaluation. Th e true baseline rate of amyloid positivity in 
the general population is diffi  cult to estimate, since 
current data are based on highly selected convenience 
cohorts that are probably enriched for AD. Given the 
strong association between age and PIB, it is likely that 
the positive predictive value of amyloid PET will be 
higher in younger patients. At present there is no clinical 
indication for amyloid imaging in cognitively normal 
individuals. But this will remain an area of active research 
in coming years, particularly with the advent of amyloid 
lowering therapies which might be most eff ective if 
initiated in the presymptomatic disease stage [34].
Mild cognitive impairment
Current data suggest that amyloid imaging provides 
prognostic information in patients with mild cognitive 
impairment (MCI), presumably by identifying patients 
with underlying AD pathology [35,36]. As a group, 52 to 
87% of MCI patients show elevated PIB binding in a 
similar regional distribution to AD [16,37]. Patients 
meet ing criteria for MCI of the amnestic subtype may be 
more likely to be PIB-positive than patients with non-
amnestic presentations [16]. 18F tracer studies report 
similar fi ndings, with positive scans found in 45 to 60% of 
MCI patients [10,11,23].
In longitudinal studies, 1-year conversion rates to AD 
range from 33 to 47% in PIB-positive MCI subjects versus 
virtually no conversions in PIB-negative subjects [38,39]. 
In the largest longitudinal eff ort to date [38], authors 
compared baseline amyloid deposition between MCI 
converters and nonconverters in 31 MCI subjects 
followed over 3 years. Overall, 55% of MCI subjects had 
increased PIB retention at baseline. Th e overall con ver-
sion rate was 82% in those with increased PIB uptake, but 
only 7% in PIB-negative subjects. Forty-seven per cent of 
PIB-positive subjects converted within 1 year, and these 
early converters showed higher tracer retention in the 
anterior cingulate and frontal cortex than late converters. 
Altogether, PIB-positive patients with MCI of the 
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amnestic subtype are likely to have early AD, and amyloid 
imaging will probably have an important role in risk 
stratifi cation and selection of patients who may benefi t 
from disease-specifi c therapies.
While amyloid PET is likely to predict whether a 
patient will convert from MCI to AD, structural/
functional imaging and cognitive tests may be better 
predictors of when an individual will convert [40]. Th is 
hypothesis is based on a model in which amyloid aggre-
gation is an early event in AD that reaches a relative 
plateau even at the MCI stage, while downstream bio-
markers measure neuronal loss and dysfunction, and 
cognitive measures are more dynamic at the symptomatic 
disease stage [13]. New consensus diagnostic guidelines 
for MCI make a distinction between biomarkers of Aβ 
deposition (amyloid PET or cerebrospinal fl uid (CSF) 
Aβ1–42 levels) and biomarkers of neuronal injury (for 
example, CSF tau, hippocampal/medial temporal atrophy 
on MRI, hypo meta bolism on FDG-PET) [41]. Biomarkers 
from both categories are used in conjunction with core 
clinical criteria to assess the likelihood that MCI is due to 
under lying AD. If both Aβ and neuronal injury markers 
are positive, a diagnosis of MCI due to AD-high 
likelihood can be made. Conversely, if markers from both 
categories are negative, MCI is considered unlikely due to 
AD. If one marker is positive and the other untested, the 
likelihood of AD is intermediate – while biomarkers are 
considered uninformative if they provide confl icting 
information.
Stratifying MCI patients into those with and without 
underlying AD may represent the major clinical use of 
amyloid imaging. MCI is a common condition, but 
clinical certainty regarding the underlying histopathology 
is low (as evidenced by the signifi cant percentage of 
classical MCI patients of the amnestic subtype who are 
PIB-negative). As with studies of normal aging, the 
generalizability of MCI studies based on highly selected 
research cohorts is questionable because these cohorts 
are enriched for AD and often exclude patients with 
comorbid illnesses that impact cognition (for example, 
cerebrovascular disease, major organ failure). Amyloid 
imaging will also be helpful in selecting MCI patients for 
clinical trials of AD-specifi c treatments initiated at the 
predementia state.
Alzheimer’s disease and variants
Most studies have found that PIB-PET has very high (90% 
or greater) sensitivity for AD [17,42]. Tracer binding is 
diff use and symmetric, with high uptake consistently 
found in the prefrontal cortex, precuneus and posterior 
cingulate cortex, followed closely by the lateral parietal, 
lateral temporal cortex, and striatum (Figure  1). Th is 
pattern closely mirrors the distribution of plaques found 
at autopsy [43]. Similar to what has been reported in NC 
and MCI, amyloid aggregation appears to be higher in 
ApoE ε4 carriers [44] – although this association is not 
always found in patients at the dementia stage [45]. 
Correlations between amyloid load and cognitive 
measures or disease severity are generally weak or absent 
[16,46]. Longitudinal studies in AD are relatively few and 
have off ered confl icting results, with some studies report-
ing minimal longitudinal change [47,48] and others 
reporting average annual increases of up to 5% in AD 
patients [11]. Regardless of whether PIB binding plateaus 
or continues to increase slowly at the dementia phase, 
brain atrophy and hypometabolism accelerate at this 
phase and correlate more robustly with disease severity 
and clinical progression [25,46].
Few studies have applied amyloid imaging to atypical 
clinical presentations of AD. One study demonstrated the 
feasibility of detecting AD pathology in middle-age 
persons with Down’s syndrome [49]. PIB-PET was used 
to demonstrate that amyloid deposition is more common 
in the logopenic variant of primary progressive aphasia 
(PPA) than in nonfl uent or semantic variants [50,51], 
supporting the hypothesis that the logopenic variant of 
PPA is predictive of underlying AD. Several studies have 
detected high PIB binding in patients with posterior 
cortical atrophy, a visuospatial/biparietal clinical syndrome 
often caused by AD [52-54]. Although single case reports 
and small series initially reported atypical binding 
patterns in PPA and posterior cortical atrophy [55], larger 
series have found a diff use binding pattern in these 
syndromes that is indistinguishable from typical AD and 
dissociated from the focal structural and metabolic 
signatures of these syndromes (see PIB and FDG in AD 
vs. logopenic variant PPA in Figure  1) [50,51,53,54]. 
Similarly, a study comparing PIB binding in early and late 
age-of-onset AD found that diff erences in cognitive 
profi les (more global defi cits in early-onset AD, and 
restricted amnesia in late-onset AD) could not be 
explained by the distribution or burden of PIB, which was 
identical in the two groups [45].
New AD diagnostic guidelines adopt a similar frame-
work to the new MCI guidelines and distinguish between 
biomarkers of Aβ deposition and neuronal injury [56]. 
Clinical and biomarker information is used in con-
junction to modify the probability of underlying AD 
pathophysiology. Th ree main categories are proposed: 
probable AD dementia, possible AD dementia (atypical 
clinical presentation), and probable or possible AD 
dementia with evidence of AD pathophysiological process. 
In typical clinical presentations, if both categories of 
biomarkers are positive, the likelihood of AD patho-
physiology is considered high. If only one of the two 
categories is positive, then the probability is intermediate. 
Atypical clinical presentations are considered at high 
probability of an AD pathophysiological process if both 
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categories of biomarkers are positive, although a second 
etiology cannot be excluded. Finally, dementia is con-
sidered unlikely due to AD when both categories of 
biomarkers are negative.
Amyloid imaging will probably not add value to the 
diagnostic work-up of patients with straightforward 
clinical AD, as these patients are very likely to have 
positive scans. Th is technique is likely to be useful in 
patients with focal cortical syndromes such as PPA and 
posterior cortical atrophy, as these are pathologically 
heterogeneous syndromes that are variably associated 
with underlying AD. Similarly, amyloid PET could be 
useful in patients with early age-of-onset dementia, as 
these patients often present with atypical symptoms (for 
example, executive, behavior, language and visuospatial 
rather than memory), and the main alternative cause of 
dementia in this age group is frontotemporal lobar 
degeneration (FTLD), a non-Aβ disease. Th e low rate of 
amyloid-positive non demented individuals in this age 
group will increase the positive predictive value of 
amyloid scans.
Cerebral amyloid angiopathy and vascular dementia
PIB binds to vascular amyloid deposits in animal models 
and postmortem human tissue [2,4,6]. Nondemented 
patients with cerebral amyloid angiopathy show high PIB 
binding compared with controls [57]. Although overall 
PIB binding is lower than in AD, cerebral amyloid 
angiopathy patients show a higher occipital-to-global PIB 
ratio, concordant with the occipital predilection of 
cerebral amyloid angiopathy at autopsy [58]. PIB may be 
useful for stratifying patients with microhemorrhages 
into those with underlying cerebral amyloid angiopathy 
and those in which hemorrhages are due to small-vessel 
vasculopathy, particularly when the anatomic distribution 
of hemorrhages is ambiguous (for example, both lobar 
and deep gray matter). Th is distinction may impact 
decisions regarding anticoagulation. It may also be 
important to distinguish AD patients with and without a 
signifi cant burden of cerebral amyloid angiopathy, as the 
latter may be at higher risk for complications from 
amyloid modifying therapies [33]. It is not yet clear 
whether PIB will be useful for this purpose (for example, 
based on occipital to global binding ratios) or add value 
to MRI sequences that are sensitive to microhemorrhages 
[59].
Vascular dementia can be diffi  cult to diff erentiate from 
AD on clinical grounds [60]. Th e two share risk factors, 
are often comorbid, and may interact biologically. Few 
studies have applied amyloid PET to patients with 
suspected vascular dementia. One study found that 69% 
of patients clinically diagnosed with subcortical vascular 
Figure 1. Amyloid tracer binding. Typical 11C-labeled Pittsburgh Compound B (PIB) binding and 18F-fl uorodeoxyglucose (FDG) hypometabolism 
patterns in normal controls (NC), Alzheimer’s disease (AD), logopenic variant of primary progressive aphasia (lvPPA), behavioral variant 
frontotemporal dementia (bvFTD), and semantic variant of primary progressive aphasia (svPPA). DVR, distribution volume ratio; SUVR, standardized 
uptake value ratio.
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dementia were PIB-negative [61]. Younger age and a 
greater number of lacunes predicted a negative PIB scan. 
Another study found high PIB binding in 40% of patients 
with post-stroke dementia [62]. PIB-positive post-stroke 
patients declined more rapidly on the Mini-Mental State 
Examination (MMSE) than did PIB-negative patients. 
Altogether, amyloid PET will probably have a clinical role 
in identifying cognitively impaired patients with high 
vascular burden who also have comorbid AD (and thus 
may benefi t from AD treatments), and will further our 
understanding of how AD and vascular disease interact 
and contribute to cognitive decline in the aging brain.
Parkinson’s disease and dementia with Lewy bodies
Th e percentage of PIB-positive scans in patients with 
dementia with Lewy bodies (DLB) has ranged between 
30 and 85% in small case series [63-67]. Similar variations 
have been reported in Parkinson’s disease dementia (15 
to 100% PIB-positive). PIB scans were negative in two 
patients with multiple system atrophy [68], and 
fl orbetaben-PET was negative in fi ve patients with 
Parkinson’s disease without dementia and positive in 29% 
of clinically diagnosed DLB patients [11]. Th ese diff er-
ences may be explained both by cohort factors and by the 
method of defi ning scan positivity (for example, 
qualitative vs. quantitative, thresholds, and so forth).
Th e pattern of binding in DLB and Parkinson’s disease 
dementia is similar to AD, although overall binding is 
lower with higher intersubject variability. Most studies 
have found higher amyloid plaques in DLB than in 
Parkinson’s disease dementia or nondemented Parkin-
son’s disease patients, and in some studies PIB-positivity 
was asso ciated with greater cognitive defi cits and more 
rapid disease progression [66]. Overall, these fi ndings are 
concordant with autopsy-based studies on the frequency 
and impact of Aβ plaques in DLB and Parkinson’s disease 
dementia [69]. In vitro and postmortem studies suggest 
that the in vivo PET signal in synuclein disorders refl ects 
PIB binding to Aβ deposits rather than to Lewy bodies 
[2,5]. Given the high frequency of amyloid plaques and 
generally high rates of positive amyloid scans in DLB, it is 
unlikely that amyloid PET will be helpful in diff erentiating 
DLB from AD. Amyloid PET may diff erentiate Parkin-
son’s disease or Parkinson’s disease dementia from AD, 
but this diff er en tiation can usually be accomplished 
clinically. Further work is needed to determine whether 
amyloid PET can provide prognostic information in 
synuclein disorders.
Frontotemporal lobar degeneration spectrum disorders
FTLD is an umbrella term used for disorders associated 
with neurodegeneration of the frontal and anterior 
temporal lobes [70]. Clinical syndromes that fall in the 
FTLD spectrum include the behavioral variant of 
fronto temporal dementia (bvFTD), frontotemporal 
dementia with motor-neuron disease, and the semantic 
and non fl uent variants of PPA [71,72]. Histopathology in 
FTLD is heterogeneous, with most cases featuring tau 
(Pick’s disease, corticobasal degeneration and progressive 
supra nuclear palsy), TDP-43 or fused-in sarcoma protein 
inclusions [73]. FTLD and AD are the leading causes of 
early age-of-onset dementia, occurring with similar 
frequency in patients presenting younger than the age of 
65 [74]. Distinguishing the two during life can be chal-
leng ing due to clinical and anatomic overlap, and mis-
diagnosis rates of 10 to 40% are reported even in expert 
centers [75].
Diff erentiating AD from FTLD is an important clinical 
use for amyloid PET, since Aβ plaques are not part of the 
FTLD pathologic spectrum, and the diff erential diagnosis 
comes up in young patients in whom age-related amyloid 
aggregation is less common. Small case series reported 
low rates of PIB (0 to 15%) and fl orbetaben-positivity 
(9%) in FTLD (see bvFTD and semantic variant PPA in 
Figure  1) [11,67,76]. Diff erentiating AD and FTLD was 
the focus of the largest study on the diagnostic utility of 
amyloid PET published to date [42]. In 62 AD patients 
and 45 FTLD patients matched for age and disease 
severity, PIB visual reads had a higher sensitivity for AD 
than FDG-PET (89.5% vs. 77.5%), with similar specifi city 
(83% vs. 84%). When scans were classifi ed quantitatively, 
PIB had higher sensitivity (89% vs. 73%) while FDG had 
higher specifi city (83% vs. 98%). PIB outperformed FDG 
in classifying 12 patients with known histopathology 
(97% vs. 87% overall accuracy). PIB visual reads also 
showed higher inter-rater reliability and agreement with 
quantitative classifi cation than FDG, suggesting it was 
the more accurate and precise technique.
Corticobasal syndrome (CBS) is sometimes included 
under the FTLD umbrella because of considerable 
clinical and pathologic overlap [77]. While most cases of 
clinical CBS are associated with FTLD pathology 
(although not necessarily corticobasal degeneration), 25 
to 50% of patients are found to have AD as the causative 
pathology postmortem [75,77,78]. Amyloid PET would 
theoretically be useful in identifying CBS patients with 
underlying AD, but clinical studies are lacking. In our 
center PIB was positive in a patient with CBS found to 
have AD/DLB at autopsy (see Figure 2, Case 4), while PIB 
scans were negative in two CBS patients with patho-
logically confi rmed corticobasal degeneration (unpub-
lished data).
Other conditions
Clinical symptoms and imaging fi ndings suggestive of 
normal pressure hydrocephalus (NPH) overlap with those 
found in neurodegenerative diseases, and AD pathology 
is found in a signifi cant proportion of patients clinically 
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diagnosed with NPH [79]. In some studies, the presence 
of AD pathology predicted poor response to shunting 
[80], prompting a few centers to routinely obtain cortical 
biopsies prior to shunting suspected NPH [81]. Two 
studies have compared PIB-PET [81] or fl utemetamol-
PET [12] with frontal biopsy results in patients with 
suspected NPH. Combined, PET scans were positive in 
eight out of nine biopsy-positive patients, and negative in 
eight out of eight biopsy-negative cases. Strong corre la-
tions were found between regional tracer uptake and 
quantitative measures of Aβ in both studies. Further work 
is needed to determine the prognostic value of amyloid 
PET in the evaluation of NPH, and to study the proposed 
biological relationships between AD and NPH [82].
PIB scans were negative in three small series featuring a 
range of prion disorders, including sporadic Creutzfeldt–
Jakob disease, variant Creutzfeldt–Jakob disease, and a 
range of prion protein mutations [83,84]. Genetic prion 
disease can occasionally present insidiously and mimic 
AD, while DLB can present as a rapidly progressive 
dementia and be mistaken for Creutzfeldt–Jakob disease. 
However, prion disease can usually be distinguished from 
Aβ-associated diseases on clinical grounds and based on 
characteristic MRI fi ndings [85].
A study of PIB in HIV-positive individuals found that 
cognitively impaired patients with HIV do not show high 
PIB binding (although some showed low levels of CSF 
Aβ1–42), suggesting that PIB may distinguish HIV dementia 
from AD, a diagnostic dilemma that will become 
increasingly relevant with an aging HIV-positive 
population [86].
Amyloid PET applied to clinically challenging cases
We have applied amyloid and FDG-PET to over 200 
patients followed in dementia research cohorts at the 
University of California San Francisco Memory and 
Aging Center as part of an ongoing study on the utility of 
these techniques in diff erential diagnosis. Figure 2 shows 
PIB and FDG scans from four clinically challenging cases, 
described in the vignettes below.
Case 1 is an 89-year-old man with 8 years of progressive 
memory loss, executive dysfunction, behavioral changes, 
and an MMSE of 29. MRI showed severe hippocampal 
atrophy as well as signifi cant subcortical white matter 
disease and a number of lacunes. Clinical diagnosis was 
mixed AD/vascular dementia. FDG showed bifrontal 
hypometabolism sparing the temporo-parietal cortex, 
while PIB revealed diff use cortical binding. Autopsy 
indicated high-likelihood AD (CERAD frequent/Braak 
stage 6) and moderate subcortical ischemic vascular 
disease. In this case, FDG alone could have led to a 
misdiagnosis of pure vascular disease or bvFTD (the 
latter less likely based on age), and treatment with a 
cholinesterase inhibitor may not have been off ered.
Figure 2. Clinically challenging cases imaged with 11C-labeled Pittsburgh Compound B and 18F-fl uorodeoxyglucose. Autopsy diagnosis is 
available in three cases. See text for a description of the cases. FDG, 18F-fl uorodeoxyglucose; PIB, 11carbon-labeled Pittsburgh Compound B; DVR, 
distribution volume ratio; SUVR, standardized uptake value ratio.
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Case 2 is a 55-year-old man with 9 years of profound 
behavioral changes including compulsive behaviors, 
disinhibition, socially inappropriate behavior, and impair-
ment in executive, memory, and visuospatial functions 
(MMSE = 16). He was clinically diagnosed with bvFTD. 
FDG showed bilateral frontal and temporo-parietal 
hypo metabolism, while PIB revealed diff use cortical 
binding. Pathology is not available. In this case, PIB 
provides a useful tiebreaker in favor of AD in an early-
onset dementia patient in whom clinical features and 
FDG-PET are ambiguous between AD and FTLD. A 
cholinesterase inhibitor was subsequently started.
Case 3 is a 70-year-old woman presenting with non-
fl uent variant PPA (MMSE = 28). FDG showed focal left 
frontal hypometabolism, while PIB was unexpectedly 
positive. On autopsy the patient was found to have both 
Pick’s disease and high-likelihood AD (CERAD frequent/
Braak 5). Th is case demonstrates that while PIB can 
accurately detect AD pathology, a positive amyloid scan 
does not rule out comorbid non-Aβ pathology, which in 
this case was FTLD, as predicted based on the clinical 
presentation and FDG-PET pattern.
Case 4 is a 68-year-old man with 6 years of progressive 
asymmetric left-sided apraxia, Parkinsonism, dystonia, 
tremor, and myoclonus. Levodopa treatment was un-
helpful. Cognitive decline was characterized by defi cits in 
executive and visuospatial functions, episodic memory 
and language (MMSE = 19). Visual hallucinations 
emerged later in the course. Clinical diagnosis was CBS. 
FDG revealed asymmetric right posterior frontal and 
temporo-parietal hypometabolism. Pathological diagnosis 
was mixed high-likelihood AD (CERAD frequent/Braak 6)/
intermediate-likelihood DLB. In this case, PIB correctly 
predicted underlying AD in a patient with a clinical 
syndrome (CBS) associated with varied histopathology.
Amyloid PET in clinical practice: unresolved 
questions and recommendations
Th ere are many unknowns that could impact the 
diagnostic utility of amyloid PET. First, the sensitivity and 
specifi city compared with pathology are not yet well 
defi ned. Technical and patient factors that could lead to 
false positives and false negatives are not clear. PIB binds 
to both diff use and neuritic plaques [6] (the latter being 
more common in normal aging), and the relative 
contribution of each to the in vivo signal has not been 
determined. It is not yet clear whether amyloid PET 
should be interpreted as a dichotomous test (that is, 
positive versus negative) or whether the degree and 
spatial distribution of binding off er additional diagnostic 
information. Studies examining inter-rater and intra-
rater reliability of visual interpretations are few, and the 
optimal quantitative threshold for defi ning a positive 
scan has not yet been defi ned [87]. Also not yet 
estab lished is whether the threshold for PIB-positivity 
should be adjusted based on demographic factors such as 
age (as is done when scoring plaques at autopsy) [43] or 
genetic variables such as the ApoE ε4 genotype. 
Signifi cantly, the relationship between amyloid and 
dementia is weaker in older versus younger individuals 
[88]. Th e positive predictive value of a positive amyloid 
scan in determining the cause of dementia will therefore 
be lower in older individuals. In general, amyloid PET 
will be more useful in ruling out (given the high 
sensitivity for pathology) than in ruling in AD as the 
cause of dementia, since the detection of amyloid may be 
incidental or secondary to a primary, non-Aβ pathology 
in some cases (for example, Case 3 above).
Th e ideal combination of biomarkers in the evaluation 
of dementia will probably depend on the specifi c clinical 
scenario. In general, the approach introduced in the new 
AD diagnostic guidelines (one marker specifi c for Aβ, 
another specifi c for neurodegeneration to establish AD 
as the probable pathophysiology) has face validity [56]. 
However, one can imagine that an amyloid scan will add 
more diagnostic value to a structural image in a 60 year 
old with an atypical MCI syndrome and hippocampal 
atrophy (which may or may not be due to AD pathology) 
than in an 80 year old with clinically classical AD 
dementia and a clear temporo-parietal cortical atrophy 
pattern. A number of studies have evaluated the utility of 
combining amyloid scans with MRI [25] or FDG [89,90], 
but these analyses have largely been limited to the MCI/
AD continuum. Also, the relative diagnostic strengths of 
CSF versus amyloid imaging as molecular markers have 
yet to be determined. While amyloid tracer binding 
correlates highly with CSF Aβ1–42 levels across the AD 
continuum [91], how CSF AD biomarkers and amyloid 
imaging compare in diff erentiating AD from other causes 
of dementia remains to be seen. Initial studies suggest 
that CSF Aβ1–42 may be more sensitive than PIB to early 
amyloid pathology [20,92], rendering CSF potentially 
more sensitive for early detection but less specifi c in 
determining the cause of dementia. Th e lack of specifi city 
may be overcome, however, by applying a ratio of Tau/
Aβ1–42 or phospho-tau/Aβ1–42 [93]. Further head-to-head 
studies of amyloid PET and CSF are needed to clarify 
these points. For current practice, we recommend 
structural neuroimaging as the standard of care for ruling 
out nondegenerative causes of cognitive decline [94]. A 
molecular marker (either amyloid PET or CSF) may have 
added value in particular scenarios, as discussed below. 
In some clinical scenarios, a nonamyloid molecular tracer 
may be preferred (for example, dopamine imaging for 
diff erentiating AD and DLB) [95].
Ultimately, to be widely adopted a diagnostic test needs 
to have a signifi cant impact on patient management and 
outcomes, and to be cost-eff ective. Few studies have 
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examined these points with regard to amyloid imaging. 
In our clinic, PIB results have had implications for treat-
ment, mainly aff ecting decisions about whether to initiate 
or discontinue AD symptomatic medications (see case 
histories). In practice, these medications are probably 
prescribed to a large number of patients with non-AD 
dementia, whereas certain populations that may benefi t 
are currently not treated (for example, MCI due to AD) 
based on negative clinical trials that may have been 
confounded by biological heterogeneity [96]. Such 
decisions would be more rational if amyloid PET was 
applied in the right circumstances, and this could result 
in cost saving. Th e more immediate impact of amyloid 
imaging will be in improving clinical trial design by 
enrolling patients based on biological, rather than 
clinical, phenotype. Th is is a necessary fi rst step for the 
development and testing of disease-specifi c therapies. 
Initial studies have found that requiring a positive 
molecular biomarker for inclusion will render AD clinical 
trials more effi  cient and less costly, especially in early 
disease stages [97]. In fact, a positive amyloid scan may 
be the primary inclusion criterion for a study focused on 
AD prevention.
Recommendations for potential clinical applications of 
amyloid PET are provided in Table 1. Th ese applications 
are based on our analysis of the data and our institutional 
experience, and represent an early attempt to guide 
clinicians in how to apply amyloid PET to their practice. 
Th e recom menda tions were formulated using the 
following principles: amyloid PET cannot be interpreted 
in the absence of clinical context (as is the case with any 
diagnostic test); amyloid PET will be most useful in 
diff erentiating Aβ from non-Aβ causes of dementia in 
scenarios in which this distinction is clinically challeng-
ing  – these scenarios might include patients with mild 
symptoms (for example, MCI), cases presenting with 
pathologically heterogeneous clinical syndromes (for 
example, PPA, CBS), patients with early age-of-onset 
dementia, or cases with symptoms that could be explained 
by either Aβ processes or nondegenerative causes (for 
example, NPH, intracranial microhemor rhages); and, fi nally, 
some very important applications of amyloid PET should 
be restricted to research studies (for example, scanning 
asymptomatic or minimally sympto matic patients).
Conclusions
While amyloid imaging has produced an impressive body 
of research in a short time, studies of practical clinical 
applications for this technology lag far behind studies 
with more biological objectives. Since clinical use is now 
feasible and will probably be approved by regulatory 
agencies in the near future, it is imperative that the 
diagnostic performance, added clinical value, and cost-
eff ectiveness of this technique be studied systematically 
Table 1. Clinical and research utility of amyloid imaging
Potential clinical utility
1. Determine whether MCI is due to AD
2. Diff erentiate AD from non-AD dementia (for example, frontotemporal lobar degeneration), particularly in early age-at-onset patients
3. Determine whether AD copathology is present in patients with cognitive impairment and other known neurologic disease (for example, Parkinson’s 
disease, stroke/vascular disease, multiple sclerosis, epilepsy, HIV)
4. Diff erentiate AD from nondegenerative cognitive decline (for example, depression, substance abuse)
5. Determine whether AD is present in patients with advanced dementia and no reliable history
6. Identify whether AD is present in focal cortical syndromes (for example, posterior cortical atrophy, primary progressive aphasia, corticobasal syndrome)
7. Diff erentiate cerebral amyloid angiopathy from intracranial hemorrhage due to small-vessel vasculopathy
Unlikely to have clinical utility
1. Initial investigation of cognitive complaints (in the absence of a detailed neurologic evaluation and cognitive testing)
2. Diff erentiate AD from other amyloid-beta-associated dementia (for example, dementia with Lewy bodies, cerebral amyloid angiopathy)
3. Diff erentiate between AD clinical variants (for example, classic amnestic AD vs. posterior cortical atrophy or logopenic variant primary progressive aphasia)
4. Diff erentiate between non-AD causes of dementia (for example, molecular subtypes of frontotemporal lobar degeneration)
Utility for research only
1. Testing and longitudinal follow-up of asymptomatic or subjective cognitive impairments not meeting MCI criteria or at-risk individuals (for example, gene 
mutation carriers, family history of AD, apolipoprotein E ε4 allele)
2. Selection of candidates for anti-amyloid treatment trials (AD, MCI, preclinical)
3. Study of the natural evolution of amyloid burden and its role in the pathophysiology of AD and other dementias
4. Potential surrogate marker for anti-amyloid therapies
In all situations, structural imaging using magnetic resonance imaging is recommended to rule out space-occupying lesions, infl ammation, or other confounding 
conditions. AD, Alzheimer’s disease; MCI, mild cognitive impairment.
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and in populations more representative of real clinical 
practice. With all its limitations, amyloid imaging repre-
sents a major breakthrough in the evaluation of dementia 
that will doubtlessly translate into better clinical care, 
and will ultimately help guide the development of 
molecular-based therapies for these devastating illnesses.
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